STANLEY 1913 BRAND AND ARSENAL KICK OFF MULTI-YEAR PARTNERSHIP
The partnership kicks off with the launch of the Stanley 1913 x Arsenal collection - a line of premium, high-performance drinkware and barware crafted to celebrate supporters around the world who live and breathe north London, with each piece taking inspiration from the club's signature kit colour and designed for performance and style. The collection celebrates supporters who bring the same passion and spirit to their everyday lives as they do to supporting one of the world's most celebrated football clubs.
Juliet Slot, Chief Commercial Officer at Arsenal, shared,"We're proud to partner with Stanley 1913, a globally-recognised brand known for its quality, performance and style. We share values of community and belonging, and it's exciting to be able to bring our supporters together with exclusive products like the Stanley 1913 x Arsenal collection."
Ben James, General Manager, EMEA, PMI WW Brands, LLC, said, "We're excited to partner with one of Europe's most successful and culturally relevant global football clubs in Arsenal. From early in our conversations it became increasingly clear how many parallels there are between our two brands - be it our heritage or shared passion for innovation. Across Europe, football is more than a game - it's a lifestyle - and we're excited to release a collection that brings people together to celebrate shared sporting experiences."
As part of the agreement, Stanley 1913 branding will appear at Premier League and Women's Super League fixtures at Emirates Stadium starting from the 2025/2026 season. Stanley 1913 will also connect with the global Arsenal family through exclusive content featuring men's and women's first team players.
The Stanley 1913 x Arsenal collection also marks Stanley 1913's first step into stadium retail, with a long-term vision to expand further into football culture across Europe and support sustainable practices and less plastic waste on game day. This follows Arsenal becoming the first club in world football to have a net-zero target approved by the globally respected Science Based Targets initiative (SBTi).
Stanley 1913 x Arsenal Collection Includes:
Stanley 1913 x Arsenal Quencher® ProTour Flip Straw Tumbler (1.2L / 40oz)
Designed for supporters on the move, this leakproof Quencher ® features a flip straw lid for spill-free hydration. Finished in bold Arsenal Red, it's the ultimate companion for match days or for everyday on-the-go hydration.
Stanley 1913 x Arsenal Quencher® ProTour Flip Straw Tumbler (0.6L / 20oz)
For compact, grab-and-go hydration - whether you're watching from home or heading to five-a-side. Featuring the same bold design and leakproof performance in a smaller silhouette.
Stanley 1913 x Arsenal IceFlow™ Bottle with Fast Flow Lid (0.7L / 24oz)
Fuel your passion on the go. Lightweight and with a fast-flow opening and carry handle, it's built for training sessions or match-day travel.
Stanley 1913 x Arsenal Stacking Tumbler (0.47L / 16oz)
Game day pairs perfectly with the Adventure Stacking Tumbler. Compact, versatile, and stackable - ready for everything from match-day coffee runs to post-game celebrations.
The Stanley 1913 x Arsenal collection will be available to purchase beginning today at Arsenaldirect.arsenal.com, and stanley1913.com, and globally via the locations below. Follow Stanley 1913 on Instagram (@stanley_brand) for more information.
About PMI WW Brands, LLC.
PMI WW Brands, LLC manufactures, markets, and sells innovative food and beverage containers under the iconic Stanley 1913 brand.
Stanley: Built for Life® since 1913.
We have fueled the human experience since the iconic Stanley vacuum bottle revolutionized the way people enjoyed food and beverage. Today, our colorful and innovative Hydration products, including the beloved Quencher®, as well as our Cafe, Bar, Kitchen, and Hard and Soft Cooler offerings, go beyond function, elevating everyday moments with style and empowering active lifestyles. We're a community of creators, builders and inventors who believe in creating sustainable products for a better life and world that minimize our impact on the planet. Learn more at www.stanley1913.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
an hour ago
- National Post
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
Article content OSAKA, Japan — Takeda ( TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVANSE significantly impacting revenue and Core Operating Profit in line with company expectations for the quarter. The company expects these impacts to moderate in future quarters. Article content Takeda also achieved several important milestones in its R&D pipeline, reinforcing its long-term growth trajectory and underscoring its commitment to delivering sustainable value through innovation. Most notably, both Phase 3 studies of oveporexton successfully met all primary and secondary endpoints, demonstrating statistically significant improvements across doses. These results reinforce the potential of oveporexton to transform the standard of care in narcolepsy type 1. Article content In addition, Takeda received U.S. FDA approval for GAMMAGARD ® LIQUID ERC and European Commission (EC) approval for ADCETRIS ® in new indications and presented promising clinical data for rusfertide at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session. These developments underscore the strength of Takeda's late-stage pipeline and its potential to drive future growth. Article content Takeda chief financial officer, Milano Furuta, commented: Article content 'The impact of VYVANSE generic erosion on Takeda's FY2025 Q1 results was very significant, but consistent with our expectations, and there is no change to our full-year outlook announced in May. Article content 'Our late-stage pipeline continues to advance with the announcement in July of positive results from two pivotal Phase 3 studies for oveporexton in narcolepsy type 1, with both studies meeting all primary and secondary endpoints. These results represent a significant scientific milestone, and we are very excited about the potential for our late-stage pipeline to deliver value to the patients we serve and to position Takeda for sustainable growth.' Article content Core (Non-IFRS) (Billion yen, except percentages and per share amounts) FY2025 Q1 FY2024 Q1 vs. PRIOR YEAR (Actual % change) vs. PRIOR YEAR (CER % change) Revenue 1,106.7 1,208.0 -8.4% -3.7% Operating Profit 321.8 382.3 -15.8 % -11.9% Margin 29.1% 31.6% -2.6 pp ― Net Profit 237.0 276.8 -14.4% -10.3% EPS (Yen) 151 176 -14.1% -10.0% Article content FY2025 Outlook (unchanged from May 2025) (Billion yen, except percentages and per share amounts) FY2025 FORECAST FY2025 MANAGEMENT GUIDANCE Core Change at CER (Non-IFRS) Revenue 4,530.0 — Core Revenue (Non-IFRS) 4,530.0 Broadly flat Operating Profit 475.0 — Core Operating Profit (Non-IFRS) 1,140.0 Broadly flat Net Profit 228.0 — EPS (Yen) 145 — Core EPS (Yen) (Non-IFRS) 485 Broadly flat Adjusted Free Cash Flow (Non-IFRS) 750.0-850.0 — Annual Dividend per Share (Yen) 200 — Article content Additional Information About Takeda's FY2025 Q1 Results Article content For more details about Takeda's FY2025 Q1 results, commercial progress, pipeline updates and other financial information, including key assumptions in the FY2025 forecast and management guidance as well as definitions of non-IFRS measures, please refer to Takeda's FY2025 Q1 investor presentation (available at Article content Article content ). Article content About Takeda Article content Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit Article content . Article content For the purposes of this notice, 'press release' means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ('Takeda') regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. Article content The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, 'Takeda' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words 'we', 'us' and 'our' are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Article content The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners. Article content Forward-Looking Statements Article content This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could', 'anticipates', 'estimates', 'projects', 'forecasts', 'outlook' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: Article content Article content .Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results. Article content Takeda's financial statements are prepared in accordance with International Financial Reporting Standards ('IFRS'). Article content This press release and materials distributed in connection with this press release include certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core Operating Profit, Core Net Profit for the year attributable to owners of the Company, Core EPS, Constant Exchange Rate ('CER') change, Net Debt, Adjusted Net Debt, EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow. Takeda's management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. Takeda's non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as 'reported' measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS measures to their most directly comparable IFRS measures, which are in the Financial Appendix appearing at the end of our FY2025 Q1 investor presentation (available at Peak Sales and PTRS Estimates Article content References in this press release to peak revenue potential ranges are estimates that have not been adjusted for probability of technical and regulatory success (PTRS) and should not be considered a forecast or target. These peak revenue potential ranges represent Takeda's assessments of various possible future commercial scenarios that may or may not occur. Article content References in this press release to PTRS are to internal estimates of Takeda regarding the likelihood of obtaining regulatory approval for a particular product in a particular indication. These estimates reflect the subjective judgment of responsible Takeda personnel and have been approved by Takeda's Portfolio Review Committee for use in internal planning. Article content Medical information Article content This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. Article content Article content Article content Article content Contacts Article content Investor Relations Article content Article content Christopher O'Reilly Article content Article content Article content Article content Article content Media Relations Article content Article content Brendan Jennings Article content Article content Article content Article content Article content Article content Article content
Cision Canada
4 hours ago
- Cision Canada
Furniture China 2025 & Maison Shanghai: Shaping Tomorrow's Furniture World
SHANGHAI, July 30, 2025 /CNW/ -- From September 9 to 13, 2025, the global furniture industry will gather in Shanghai Pudong for the landmark 30th edition of Furniture China and the newly upgraded Maison Shanghai. Jointly organized by China National Furniture Association and Shanghai Sinoexpo Informa Markets, Furniture China 2025 & Maison Shanghai will be spanning 50 halls across two venues — SNIEC (Shanghai New International Expo Centre) and SWEECC (Shanghai World Expo Exhibition & Convention Center) — the dual events will welcome over 3,200 exhibitors and an estimated 200,000 visitors from around the world, featuring cutting-edge furniture collections, design showcases, and sustainable solutions over 350,000 sqm of exhibition space. Highlights include a dedicated Garden Furniture Pavilion in hall E8B at SNIEC, complemented by outdoor design showcases in halls E6 and famous outdoor brands in hall N2. Visitors will find weather-resistant loungers, modular seating, dining sets, and eco-friendly accessories to transform outdoor spaces into elegant retreats. As ESG values become integral to design and commerce, the ReMe: ESG Sustainability Themed Exhibition (Booth E5D12, SNIEC) presents a visionary green concept space, promotes recycling and low-carbon design via immersive installations and forums. Running concurrently with Furniture China, FMC China and FMC Premium bring together global leaders in furniture components, raw materials, and manufacturing technologies, offering a comprehensive look at the upstream power driving furniture excellence. Exhibitors from 15+ countries will present cutting-edge technologies, making FMC a key link between design and industrial production. At SWEECC, from September 9 to 12, Maison Shanghai will spotlight the evolving landscape of design under the theme "Design Infinity". Divided into four thematic zones (H1–H4), it brings together 800+ design-driven brands and showcases concepts across lifestyle curation, original art-inspired furniture, and material innovation. Maison Shanghai will also host 100+ forums and diverse events, including the Gold Idea Design Award, CREDAWARD, Design of Designers (DOD), and the influential Maison Design Forum, providing global insights into design's commercial and cultural value. The upgraded DTS FurnitureChina App enables online-offline integration, supporting pre-registration, business matching, and 24/7 trade. Save the Dates: FURNITURE CHINA 10-13 September 2025 | SNIEC Full-spectrum trade show for furniture & materials MAISON SHANGHAI 9-12 September 2025 | SWEECC Future-forward design, lifestyle furnishing, and factory-direct sourcing Register now here.
Globe and Mail
4 hours ago
- Globe and Mail
China Southern Power Grid Showcases Multiple AI Achievements at 2025 World Artificial Intelligence Conference
SHANGHAI , /CNW/ -- From July 26 to 28 , the 2025 World Artificial Intelligence Conference (WAIC) convened in Shanghai under the theme "Global Solidarity in the AI Era." As a strategic partner of the event, China Southern Power Grid (CSG) unveiled an exhibition themed "Empowering Every kwh with AI" and hosted a forum focused on AI-driven innovation in the power sector. CSG also presented a range of AI-powered applications at the China AI Industry Innovation Exhibition, highlighting its latest initiatives to integrate AI into energy and power systems and support the growth of a smarter industrial ecosystem. In recent years, CSG embraced emerging technologies—particularly artificial intelligence—and achieved a number of breakthrough advances. These include strengthening its technological foundation, deploying a wide range of demonstration scenarios, and helping build an AI ecosystem within the power sector. These efforts have played a key role in building the New Energy System and the New Power System and serving the industry's transition to low-carbon and environmentally responsible operations. Looking ahead, CSG will continue to prioritize national strategic objectives, including the Digital China initiative and the broader energy transition. The company plans to deepen its research into AI technologies and expand their application across the energy sector, while strengthening collaboration across the industry value chain. Through these efforts, CSG aims to contribute Chinese solutions and expertise to the global digital and intelligent transformation of the energy industry, and to the long-term goals of carbon peaking and carbon neutrality.
